Stem Cell transplantation is in the infant stages for this disease; however it is promising. Reports on allo-SCT in T-cell lymphoma have been encouraging. The largest series by Corradini et al. reported on 17 patients with a median age of 14 years, of whom 8 patients had failed an autograft. The estimated 3-year OS and PFS rates were 81% and 64%, respectively. TRM at 2 years was 6% and DLI induced a response in 2 patients progressing after allografting. Wulf et al. reported on 10 patients with relapsed or primary progressive T-cell lymphoma. Patients received salvage therapy consisting of alemtuzumab with or without chemotherapy and received RIC (fludarabine, busulfan, cyclophosphamide) followed by allo-SCT. With a median follow-up of seven months 7 patients remained alive, 6 in complete remission. Surprisingly good results were also reported by Kim et al. and Kusumi et al. All these are retrospective series. Nevertheless, NCCN lists stem cell transplantation as an option.
Norbert Schmitz, Peter Dreger, Bertram Glass, Anna Sureda Allogeneic transplantation in lymphoma: current status Haematologica, Vol 92, Issue 11, 1533-1548
Au WY, Lie AKW, Liang R, et al: Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value. Ann Oncol 14:1673-1679, 2003
L. Pagano, A. Gallamini, G. Trape, L. Fianchi, D. Mattei, G. Todeschini, A. Spadea, S. Cinieri, E. Iannitto, M. Martelli, A. Nosari, E. D. Bona, M. E. Tosti, M. C. Petti, P. Falcucci, M. Montanaro, A. Pulsoni, L. M. Larocca, G. Leone, and For the Intergruppo Italiano Linfomi NK/T-cell lymphomas ‘nasal type’: an Italian multicentric retrospective survey Ann. Onc., May 1, 2006; 17(5): 794 – 800.
NCCN.ORG, NHL. T-CELL 3. 2012
Kimiharu Uozumi Treatment of Adult T-cell Leukemia J Clin Exp Hematopathol Vol. 50, No. 1, May 2010
http://www.bcshguidelines.com/documents/T-cell_guideline_final_bcsh.pdf , 2012